An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays.

PubWeight™: 0.85‹?›

🔗 View Article (PMID 8639468)

Published in J Steroid Biochem Mol Biol on March 01, 1996

Authors

J W Chapman1, B G Mobbs, D R McCready, H L Lickley, M E Trudeau, W Hanna, H J Kahn, C A Sawka, E B Fish, K I Pritchard

Author Affiliations

1: Henrietta Banting Breast Centre, Women's College Hospital, Toronto, Ontario, Canada.

Articles by these authors

The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst (1996) 5.28

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 4.24

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1998) 3.78

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol (2005) 3.62

Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med (1997) 3.57

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol (1998) 2.42

Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev (2001) 2.35

Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst (1992) 2.31

Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol (1999) 2.29

Multivariate matching and bias reduction in the surgical outcomes study. Med Care (2001) 2.19

Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback. J Clin Oncol (1998) 1.97

New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem (1996) 1.94

Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol (1999) 1.92

Role of antibody to S100 protein in diagnostic pathology. Am J Clin Pathol (1983) 1.80

Randomized trial of a patient decision aid for choice of surgical treatment for breast cancer. Med Decis Making (2001) 1.68

Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol (2011) 1.64

Factors associated with negative margins of lumpectomy specimen: potential use in selecting patients for intraoperative radiotherapy. Ann Surg Oncol (2007) 1.51

Assessment of treatment for patients with primary ductal carcinoma in situ in the breast. Ann Surg Oncol (1998) 1.49

Outcomes after localized axillary node recurrence in breast cancer. Ann Surg Oncol (2003) 1.47

The correlation of Ki67 growth factor and ERICA in breast cancer. Mod Pathol (1992) 1.44

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol (2003) 1.44

Factors associated with local breast cancer recurrence after lumpectomy alone: postmenopausal patients. Ann Surg Oncol (2000) 1.44

Systemic adjuvant therapy for node-negative breast cancer. CMAJ (1989) 1.42

A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12). Ann Oncol (2009) 1.40

Pretibial epidermolysis bullosa: report of a case. J Am Acad Dermatol (1990) 1.40

Sedation for upper gastrointestinal endoscopy: a comparative study of midazolam and diazepam. Gastrointest Endosc (1989) 1.40

Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Ann Oncol (1992) 1.39

Pseudoporphyria cutanea tarda: two case reports on children receiving peritoneal dialysis and erythropoietin therapy. J Pediatr (1992) 1.38

Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol (2012) 1.37

The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med (1985) 1.28

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24

Immunohistochemical and electron microscopic assessment of childhood rhabdomyosarcoma. Increased frequency of diagnosis over routine histologic methods. Cancer (1983) 1.23

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer (2012) 1.22

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol (2002) 1.21

The uptake of tritiated oestradiol by dimethylbenzanthracene-induced mammary tumours of the rat. J Endocrinol (1966) 1.21

Salivary gland components involved in the formation of squamous metaplasia. Am J Pathol (1985) 1.18

Malignant myoepithelioma of the breast. An immunohistochemical study by light and electron microscopy. Cancer (1986) 1.18

Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2000) 1.16

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol (2010) 1.14

Origin of the desmoplasia in desmoplastic malignant melanoma. Hum Pathol (1983) 1.11

Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res (1993) 1.11

S-100 protein antibodies do not label normal salivary gland myoepithelium. Histogenetic implications for salivary gland tumors. Am J Pathol (1991) 1.09

Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs. J Clin Invest (1992) 1.08

The surgical and oncologic significance of the axillary arch during axillary lymphadenectomy. Can J Surg (1997) 1.08

Protection against aspirin-induced antral and duodenal damage with enprostil. A double-blind endoscopic study. Gastroenterology (1985) 1.08

Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann Surg Oncol (2000) 1.06

In situ duct carcinoma of the breast: clinical and histopathologic factors and association with recurrent carcinoma. Breast J (2002) 1.06

Cigarette smoking reduces human gastric luminal prostaglandin E2. Gut (1985) 1.05

Extracellular activities of human granzymes. I. Granzyme A induces IL6 and IL8 production in fibroblast and epithelial cell lines. Cell Immunol (1996) 1.05

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol (2012) 1.05

Sclerosing peritonitis associated with luteinized thecomas of the ovary. A clinicopathological analysis of six cases. Am J Surg Pathol (1994) 1.04

Hereditary breast cancer. Risk assessment of patients with a family history of breast cancer. Can Fam Physician (1999) 1.04

Advanced scleroderma bowel: complications and management. J Rheumatol (1988) 1.04

International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol (2012) 1.04

Interactions between glucagon and other counterregulatory hormones during normoglycemic and hypoglycemic exercise in dogs. J Clin Invest (1984) 1.03

Gastric phytobezoar following gastrectomy. Can Med Assoc J (1971) 1.02

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol (2000) 1.02

Immunohistochemistry of intravascular papillary endothelial hyperplasia. J Cutan Pathol (1990) 1.02

DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. Cancer Treat Rep (1981) 1.01

Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment. Eur J Cancer Clin Oncol (1987) 1.01

Population-based home care services in breast cancer: utilization and costs. Curr Oncol (2012) 1.01

Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res (1986) 1.01

Myoepithelial cells in salivary gland tumors. An immunohistochemical study. Arch Pathol Lab Med (1985) 1.00

Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat (2001) 0.99

Tumour characteristics among women with very low-risk breast cancer. Breast Cancer Res Treat (2012) 0.99

Primary angiosarcoma of the spleen: a case report and review of the literature. South Med J (1995) 0.99

The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr Oncol (2009) 0.98

Salivary gland monomorphic adenoma. Ultrastructural, immunoperoxidase, and histogenetic aspects. Am J Pathol (1984) 0.98

Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. J Clin Oncol (1997) 0.97

Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol (R Coll Radiol) (2011) 0.96

Femoral hernia in children. J Pediatr Surg (1966) 0.96

Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. J Am Coll Nutr (1989) 0.96

Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions. Comparison with intermediate filament distribution by electron microscopy. Am J Pathol (1982) 0.96

Prostaglandin biosynthesis by gastric mucosa. II. Studies in man. Clin Biochem (1984) 0.95

The rise of tamoxifen: temporal and geographical trends of tamoxifen use in Ontario. Breast Cancer Res Treat (1997) 0.95

Benign and malignant breast disease: the relationship between women's health status and health values. Med Decis Making (1991) 0.95

The Fox guarding the clinical trial: internal vs. external validity in randomized studies. Psychooncology (1999) 0.95

Histopathological patterns of melanoma metastases in sentinel lymph nodes. J Clin Pathol (2004) 0.95

Ultrastructure of the esophageal muscle in achalasia and diffuse esophageal spasm. Am J Clin Pathol (1983) 0.95

Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Res Treat (2001) 0.94

Organochlorines and breast cancer risk by receptor status, tumor size, and grade (Canada). Cancer Causes Control (2001) 0.94